410074-74-7

Usage

Uses

Used in Pharmaceutical Industry:
DOV 21947 hydrochloride is used as an antidepressant and anxiolytic agent for the treatment of mood and anxiety disorders. It is utilized for its ability to increase serotonin and norepinephrine levels in the brain, which helps in regulating mood and reducing anxiety.
Used in Psychiatry:
DOV 21947 hydrochloride is used as a potential treatment for attention-deficit hyperactivity disorder (ADHD) due to its action as an SNRI, which may contribute to improved focus and reduced hyperactivity in affected individuals.
Used in Research and Development:
In the field of psychiatric research, DOV 21947 hydrochloride is used to explore the mechanisms of mood regulation and anxiety reduction, as well as to compare its efficacy and side effect profile with existing SNRIs, potentially leading to advancements in psychiatric treatment options.

Upstream product

• 67644-29-5 1-(4-chlorophenyl)-3-azabicyclo[3.1.0]hexane 
• 66504-44-7 (±)-1-(3,4 dichlorophenyl)-3-azabicyclo[3.1.0]-hexane-2,4-dione 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 877397-17-6 1-(3,4-dichlorophenyl)-1,2-cyclopropane-dicarboxylic acid dimethyl ester 
• 163339-71-7 α-bromo-3,4-dichlorophenylacetic acid methyl ester 
• 344245-65-4 1-(3,4-dichlorophenyl)-1,2-cyclopropanedicarboxylic acid 
• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 
• 910028-63-6 C₁₁H₁₂Cl₃N 
• 1004551-77-2 C₁₁H₁₃Cl₂NO 
• 86215-36-3 (+/-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0.]hexane hydrochloride 
• 67843-74-7 (S)-epichlorohydrin 

Relevant academic research and scientific papers

USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIO

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azab

PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azab

METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL -3-AZABICYCLO[3.1.0 ] HEXANES

The invention provides novel compositions and methods of making (-)-1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane and other 1-aryl-3- azabicyclo[3.1.0]hexanes, including synthetic methods that form novel intermediate compounds of the invention for pro

Novel polymorphs of azabicyclohexane

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

PROCESS FOR THE SYNTHESIS OF (+) AND (-) -1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE

The present invention is concerned with novel processes for the preparation of (+)-l-(3,4- dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (-)- l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutic

NOVEL POLYMORPHS OF AZABICYCLOHEXANE

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3, 4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

The present invention relates to (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing depression in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (?)-enantiomer.

Method of treating depression using azabicyclohexanes

The present invention concerns certain novel substituted 3-azabicyclo[3.1.0]hexanes and a method of treating depression and stress in a warm-blooded animal, comprising the administration of substituted 3-azabicyclo[3.1.0]hexanes.

Azabicyclohexanes

Substituted 3-azabicyclo[3.1.0]hexanes, acid addition salts, method of use and method of preparation are described. The compounds have anxiolytic and analgesic activity.